Company / Operating Income
Apogee Therapeutics, Inc. Operating Income History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$216.9M
FY2024
5-year range
-$216.9M / -$30.7M
FY2022-FY2024
Trend
-133.2%
vs FY2023
Sector context
#150 of 204
Health Care
What the data says
At -$217M, Apogee Therapeutics, Inc.'s operating income ranks #150 of 204 in the Health Care sector. Declined from -$31M to -$217M over the past 2 years.
Based on SEC 10-K filings.
-$217M in FY2024.
Declined from -$31M to -$217M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#150 of 204 in Health CareTop 74% of 204This company -$216.9M Sector average $107.7M
▼
-301.3% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 133.2% year-over-year.
- Ranks #150 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$216.9M | -133.2% |
| FY2023 | -$93.0M | -202.7% |
| FY2022 | -$30.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026